Massif

B-TEMIA Initiates Pivotal Clinical Trial To Support Commercial Launch Of Keeogo In The U.S.

– Partnering with three of the most reputable rehab centers in North America –

Quebec, November 23, 2015 – B-TEMIA Inc., the market leader in human augmentation, today announced that it has initiated a multi-centre pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of its powered assistive DemoskeletonTM technology, called Keeogo, for patients suffering from reduced mobility due to their medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick’s, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.

“This is the first international clinical trial involving the DermoskeletonTM technology that aims at demonstrating the efficacy and safety of Keeogo™ during everyday community and home mobility use, something that has not been possible in the past with other exoskeleton technologies that were developed principally for use in a clinical rehabilitation setting,” stated Dr. Chris A. McGibbon.

As part of the trial, B-TEMIA has partnered with three of the most reputable rehabilitation institutions in North America: the Rehabilitation Institute of Chicago, the Spaulding Rehabilitation Hospital Boston, and the Toronto Rehabilitation Institute–UHN.

“This pivotal clinical trial will be key in supporting the commercial launch of KeeogoTM in the U.S. market. Based on earlier very positive pilot studies, we are confident that it will demonstrate how Keeogo™ could significantly improve the daily activities of those who suffer from disabilities that impact their mobility,” said Mr. Stéphane Bédard, President & CEO of B-TEMIA.

www.b-temia.com

www.keeogo.com

Tags: ,

One Response to “B-TEMIA Initiates Pivotal Clinical Trial To Support Commercial Launch Of Keeogo In The U.S.”

  1. Airborne_fister says:

    As a paraplegic dude. I can say. There is a flood of exoskeletons. You have the company rewalk, this company above and finally exoskeleton. They all might work well. But when I used rewalk in the city of Indianapolis. The cross walk light would change. But I was not able to cross the street in the time the cross walk light was lite up. So if they haven’t figured out a way for the system to put you at a normal person’s pace. I’ll stick to my wheelchair and just be shorter then most.